Jones L, Ahmad S, Chan K, Verardi P, Morton W R, Grant R, Yilma T
Department of Veterinary Pathology, Microbiology, and Immunology, University of California, Davis 95616, USA.
J Med Primatol. 2000 Aug;29(3-4):231-9. doi: 10.1034/j.1600-0684.2000.290316.x.
The only vaccines shown to be protective against intravenous challenge with virulent virus in the simian immunodeficiency virus (SIV)/macaque model are attenuated live SIVs. However, these vaccines have several disadvantages: 1) they persist indefinitely in vaccinated macaques; 2) they are pathogenic to neonatal macaques; and 3) they are lethal in some adult macaques. To enhance the safety and efficacy of these vaccines, we immunized macaques first with recombinant vaccines and then inoculated the animals with SIV(delta(nef)). In the first experiment, preimmunized macaques advanced to disease slower than controls after challenge with virulent SIV; five animals survived for 3 years without disease and only the vaccine virus (SIV(delta(nef)) could be isolated at this time. In the second experiment, preimmunized animals had lower virus loads and no disease compared to controls.
